✕
Nesher Pharmaceuticals - a subsidiary of Zydus Cadila has received a nod from US health regulatory to market Oseltamivir powder. It is an oral suspension used for the treatment and prevention of influenza. It will be marketed in the strengths of 6 mg/ml.
The estimated sales of the product are said to be $367.92 million and it will be manufactured at Nesher Pharmaceuticals' manufacturing facility located in St Louis, US.
Since the commencement of the company, it has more than 150 approvals and about 300 abbreviated new drug applications.
http://www.business-standard.com/article/news-ians/zydus-nesher-gets-usfda-nod-to-market-influenza-drug-117091600855_1.html
The estimated sales of the product are said to be $367.92 million and it will be manufactured at Nesher Pharmaceuticals' manufacturing facility located in St Louis, US.
Since the commencement of the company, it has more than 150 approvals and about 300 abbreviated new drug applications.
http://www.business-standard.com/article/news-ians/zydus-nesher-gets-usfda-nod-to-market-influenza-drug-117091600855_1.html
Zydus' Nesher gets USFDA nod to market influenza drug
Nesher Pharmaceuticals - a subsidiary of Zydus Cadila has received a nod from US health regulatory to market Oseltamivir powder. It is an oral suspension used for the treatment and prevention of influenza. It will be marketed in the strengths of 6 mg/ml. The estimated sales of the product is said to be $367.92 million and it will be manufactured at Nesher Pharmaceuticals' manufacturing facility located at St Louis, US. Since the commencement of the complany, it has more than 150 approvals and about 300 abbreviated new drug applications.
Like
Comment
Share
